News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 651 results
March 2014
-
Media ReleaseNovartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients- FEATURE and JUNCTURE data show secukinumab delivered significant skin clearance at week 12(1,2)- Patients reported high satisfaction with self-administration of secukinumab pre-filled syringe or…
-
Media ReleaseNovartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
-
Media ReleaseNovartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years- Xolair® is approved for CIU patients age…
-
Media ReleaseNovartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
January 2014
-
Media ReleaseNovartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safetyPatient safety and well-being are highest priority at Novartis Pharmaceuticals Corporation (NPC) Patient adherence activities provide important education and support to help patients…
-
Media ReleaseNovartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
December 2013
-
Media ReleaseNovartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia-- Data at ASH show increased scientific understanding of CTL019 and its potential role in the treatment of certain types of lymphocytic leukemia(1,2,3,4)-- Presentations include findings that 19 of…
-
Media ReleaseNovartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
October 2013
-
Media ReleaseNovartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure CaregiversEvery 30 seconds, someone in the US is hospitalized for heart failure1; mobile solutions could play a role to help manage this disease Novartis Mobile Health Challenge attracted…
-
Media ReleaseNovartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
September 2013
-
Media ReleaseNovartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patientsStudy result signals potential kidney benefit with RLX030;1 future studies will further explore this impact Kidney dysfunction affects approximately 30 percent of US heart failure…
-
Media ReleaseNovartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients
Pagination
- ‹ Previous page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- …
- 55
- › Next page